MBRX News and Press, Moleculin Biotech Inc. From 03/22/24

2024-03-22 16:16:03 ET More on Moleculin Biotech Seeking Alpha’s Quant Rating on Moleculin Biotech Historical earnings data for Moleculin Biotech Financial information for Moleculin Biotech Read the full article on Seeking Alpha For further det...

Moleculin Reports Full Year 2023 Financial Results PR Newswire – Year marked by growing body of positive Annamycin efficacy and safety clinical data expected to support advancement into a pivotal study for AML – Company to host conference call and webcast...

Bitdeer Technologies Group (BTDR) is expected to report $0.11 for Q4 2023 BioForce Nanosciences Holdings Inc (BFNH) is expected to report for Q4 2023 Casino Guichard Perrachon ADR (CGUSY) is expected to report for quarter end 2023-12-31 Motorsport Games Inc. (MSGM) is expected to repo...

2024-03-21 09:02:03 ET Metabasis Therapeutics Inc (MBRX) announced stock split at a ratio of 1-for-15 on 2024-03-22 ... Full story available on KlickAnalytics.com

Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast PR Newswire In-depth discussion of stratification of Company's 2 nd line data of Annamycin as a therapy for acute myeloid leukemia (AML) Guidance to be provi...

2024-03-19 16:36:02 ET More on Moleculin Biotech Moleculin Biotech stock slides on pricing $4.5 million securities offering Read the full article on Seeking Alpha For further details see: Moleculin Biotech to implement a 1-for-15 reverse stock split

Moleculin to Present at the 36th Annual ROTH Conference PR Newswire Live webcast fireside chat on Monday, March 18 th at 9:00 AM PT HOUSTON , March 12, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Com...

2024-02-02 17:15:25 ET More on Moleculin Biotech Moleculin Biotech, Inc. (MBRX) Q3 2023 Earnings Call Transcript Moleculin Biotech stock slides on pricing $4.5 million securities offering Moleculin Biotech gains after early data for lead cancer therapy Seekin...

Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3 PR Newswire – MB-106 AML Phase 1B /2 trial (MB-106) preliminary data readout: Reached 67% recruitment ...

2023-12-21 01:31:33 ET More on Moleculin Biotech Moleculin Biotech gains after early data for lead cancer therapy Seeking Alpha’s Quant Rating on Moleculin Biotech Historical earnings data for Moleculin Biotech Financial information for Moleculin Biote...